Fig. 4.

Enhancement of BM-MSC-CM-derived miR-1180 on the glycolysis and chemoresistance of ovarian cancer cells

(a) Comparison of miR-1180 levels in control microRNA-or anti-miR-1180-supplemented BM-MSC-CM. (b) Proliferative curves of SKOV3 and COC1 cells in normal or miR-1180-deprived BM-MSC-CM under a cisplatin-containing condition (0.5 mg/L). (c) Colony formation abilities of SKOV3 and COC1 cells in normal or miR-1180-deprived BM-MSC-CM under a cisplatin-containing condition (0.5 mg/L). (d) The ECARs of SKOV3 and COC1 cells in normal medium or miR-1180-deprived BM-MSC-CM under a cisplatin-containing condition (0.5 mg/L). (e) ATP production of SKOV3 and COC1 cells in normal or miR-1180-deprived BM-MSC-CM under a cisplatin-containing condition (0.5 mg/L). ^* P<0.05, ^** P<0.01, ^*** P<0.001, two-sided Student’s t-test. Data are expressed as mean±standard deviation (SD)